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Surveillance for Botulism in
South Carolina
Dan Drociuk, MT, (ASCP)
Director, Enhanced Surveillance & Response
Section
DHEC, Division of Acute Disease Epidemiology
Background
Botulism is a neuroparalytic illness resulting from the
action of a potent toxin produced by the organism
Clostridium botulinum. This microbe was first described
in 1897 by E. van Ermengem after his investigation of a
foodborne outbreak in Ellezelles, Belgium1. Foodborne
botulism is rare, but it may kill rapidly, and contaminated
products may expose many persons.  The July 2007
botulism outbreaks in Indiana and Texas that were
associated with canned chili sauce have increased the
need for botulism awareness. They’ve also increased the
understanding that foodborne botulism represents a
medical and a public health emergency that places a
premium on rapid, effective communication between
clinicians and public health officials.
Surveillance
The diagnosis of botulism is not difficult when it is strongly
suspected, as in a large outbreak. But since cases of
botulism most often occur singularly, the diagnosis may
pose more of a problem. Findings from many outbreaks
have suggested that early cases are commonly
misdiagnosed.2
Surveillance for botulism cases in South Carolina is
focused on three areas:
• Foodborne botulism occurs when a person
ingests pre-formed toxin that leads to illness
within a few hours to a few days.
• Infant botulism occurs in a small number of
susceptible infants each year who harbor
C.botulinum in their intestinal tract.
• Wound botulism occurs when wounds are
infected with C. botulinum that secrete toxins.
Symptom Presentation/Epidemiology
Incubation periods for foodborne botulism are reported to
be as short as six hours or as long as 10 days, but generally
Neisseria gonorrhea Antimicrobial
Resistance: Important Considerations
for the Treatment of Sexually Transmitted
Infections
Wayne Duffus, MD, PhD
Medical Director
DHEC, Division of STD/HIV
Sexually transmitted infections (STI)
due to  Neisseria gonorrhea are a very
important public health problem. Ap-
proximately 800,000 people are in-
fected with N. gonorrhea each year at
an estimated cost of $1 billion. The
number of reported cases underesti-
mates the true prevalence of N. gonor-
rhea STIs, as many cases can be as-
ymptomatic and occur in populations
who either do not seek care or have
limited access to care. This under-
scores the need for large surveillance
surveys representative of the national
population.
Rates remain high in the southeastern
United States, especially among men
who have sex with men, minorities, and
adolescents of all racial and ethnic
groups. This high prevalence suggests
continued unprotected sexual
intercourse, and it underscores the
importance of stronger prevention
messages and education.  In particular,
those in the younger age groups may
be unaware of AIDS-related mortality
prior to the advent of highly active
antiretroviral therapy (HAART). Thus,
they may not be as cautious in their
sexual practices.
The spectrum of infection with N.
gonorrhea includes cervicitis, urethritis,
pharyngitis, and pelvic inflammatory
disease. The risk for HIV transmission
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the time between toxin ingestion and onset of symptoms
ranges from 18 to 36 hours3. The clinical syndrome of
botulism, whether foodborne, infant, or wound, is
dominated by the neurologic symptoms and signs
resulting from a toxin-induced blockade of the voluntary
motor and autonomic cholinergic junctions and is quite
similar for each cause and toxin type. Symptoms of
botulism include double vision, blurred vision, drooping
eyelids, slurred speech, difficulty swallowing, and dry
mouth. Botulism also causes muscle weakness that
always descends through the body: first shoulders are
affected, then upper arms, lower arms, thighs, calves, etc.
Botulism should be suspected in any adult with a history
of acute onset of gastrointestinal, autonomic (e.g., dry
mouth, difficulty focusing) and cranial nerve dysfunction
(diplopia, dysarthria, dysphagia) or in any infant with poor
feeding, diminished sucking and crying ability, neck and
peripheral muscle weakness, and/or ventilatory distress.
The demonstration of bilateral cranial nerve findings and
the documentation of neurologic progression (descending
peripheral muscle weakness, ventilatory compromise)
increase the level of suspicion4. The diagnosis is even
more likely if an adult patient has recently eaten home-
canned foods or if family members are similarly ill, or both.
Foodborne botulism can occur in all age groups.
Treatment
The points in the treatment of foodborne and wound
botulism are as follows:
• Administration of botulinum antitoxin in an attempt
to prevent neurologic progression of a moderate,
slowly progressive illness, or to shorten the
duration of ventilatory failure in those with a
severe, rapidly progressive illness;
• Careful monitoring of respiratory vital capacity and
aggressive respiratory care for those with
ventilatory insufficiency (monitoring of respiratory
vital capacity should be performed as soon as
diagnosis of botulism is made); and
• Meticulous and intensive care for the duration of
the often prolonged paralytic illness5.
Antitoxin therapy is more effective if undertaken early in the
course of illness.  Botulinum antitoxin, supplied by the
U.S. Centers for Disease Control and Prevention (CDC),
can prevent progression of illness and shorten symptoms
in severe botulism cases if administered early.  DHEC
and the CDC will consult with the physician treating the
patient for requests for antitoxin. If indicated, antitoxin can
be delivered from the CDC directly to the physician.
Public Health Response
Because cases of foodborne botulism result from
ingestion of contaminated food that still may be available
to cause illness in others, a single case of foodborne
botulism represents a public health emergency that might
indicate potential for a larger outbreak. Therefore, it is
critical for clinicians who suspect botulism to discuss the
case immediately with their DHEC regional public health
office. If, after this clinical consultation, antitoxin is indicated,
state public health officials will contact the CDC and
   (Continued on Page 3)
request antitoxin.  If a commercial food product is a
suspected vehicle for botulism, the U.S. Department of
Agriculture or the U.S. Food and Drug Administration will
also be notified. Investigation of a suspected case of
botulism includes an immediate search for other possible
cases and identification of suspected food exposures.
Diagnostic testing of both case specimens and foods may
be performed as needed.  If a number of people are
affected, a rapid and detailed epidemiologic investigation
will be initiated to assure the source is identified and
controlled.
Reporting:
The lack of reported human cases of botulism in recent
years, the historical use of botulism as a biological weapon,
and the need to request botulinum antitoxin directly from
the CDC, makes any suspected or confirmed case of
botulism a condition immediately reportable by phone as
per the current South Carolina List of Reportable
Conditions, available at:
h t t p : / / w w w. s c d h e c . g o v / h e a l t h / d i s e a s e / d o c s /
reportable_conditions.pdf.
References:
1 Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the
  United States: A clinical and epidemiologic review. Ann
 Intern Med. 1998; 129: 221-228.
2 St. Louis ME, Peck SH, Bowering D, et al. Botulism
  from chopped garlic: Delayed recognition of a major
  outbreak. Ann Intern Med 1988;108:363-368.
3 Woodruff BA, Griffin PM, McCroskey LM, et al. Clinical
and laboratory comparison of botulism from toxin
types A, B, and E in the United States, 1975-1988.
   J Infect Dis 1992;166:1281-1286.
4 U.S. Centers for Disease Control and Prevention:
  Botulism in the United States, 1899-1996.
  Handbook for Epidemiologists, Clinicians, and
  Laboratory Workers, Atlanta, GA. U.S. Centers for
  Disease Control and Prevention, 1998: 12.
5 Centers for Disease Control and Prevention: Botulism
   in the United States, 1899-1996.
   Handbook for Epidemiologists, Clinicians, and
   Laboratory Workers, Atlanta, GA. Centers for Disease
   Control and Prevention, 1998: 13-14.
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is also significantly increased in the presence of N.
gonorrhea STI. The potential for serious complications
and risk for HIV transmission should convince providers
in both public and private clinical practices of the need to
implement the CDC screening recommendations. More
intensive measures should be undertaken to: re-screen
after a positive test result three months after diagnosis;
anonymously notify partners of infected individuals; and
implement expedited partner therapy (delivery of antibiotic
therapy by patients directly to their partners) as appropriate
and permissible. A recent study concluded from modeling
estimates that screening of high-risk men could be a viable
Digitized by South Carolina State Library
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tool in STI control (2007 ISSTDR Conference, Abstract O-
008).
Clinically significant antimicrobial resistance by N.
gonorrhea has been the trend over the past 60 years. The
Gonococcal Isolate Surveillance Project (GISP) was
established in 1986 to monitor this trend. STI clinics in 25
- 30 U.S. cities participate each year. The first 25
gonococcal (GC) urethral isolates each month from men
attending the clinics are forwarded to regional laboratories
for antimicrobial susceptibility testing. In this sample,
resistance to ciprofloxacin did not occur until 1995, but it
appeared in 4.1 percent of isolates in 2003. In 2003, 14.4
percent and 6.5 percent of isolates were resistant to
tetracycline and penicillin, respectively, and these two
drugs have been abandoned as GC therapy in the United
States (Annals of Intern Med 2007; 147:81-88).
GISP data continues to document the rapidly rising GC
resistance to fluoroquinolones, including ciprofloxacin.
This resistance was first observed in Hawaii in the 1990s
and in California in the early 2000s. By 2003, it had become
prevalent nationally in men who have sex with men. As a
result, the current CDC guidelines do not recommend the
use of fluoroquinolones to treat gonococcal STIs in men
who have sex with men (2006 MMWR; Vol 55).
Another important observation has been the rising GC
fluoroquinolones resistance in heterosexuals. An updated
CDC treatment guideline does not recommend the use of
fluoroquinolones to treat gonococcal STIs in heterosexuals
(2007 MMWR; Vol 56). This trend threatens the use of
cheap, oral fluoroquinolones and necessitates the use of
expensive, often injectable cephalosporins. The oral
cephalosporin, Cefixime, at the time of this writing, is no
longer available. Single agent treatment for chlamydia and
GC co-infection with a tetracycline or a macrolide is
ineffective for fluoroquinolone-resistant GC because of the
frequent tetracycline resistance and high MICs of
azithromycin among GC isolates.
Geographic location dramatically influences the prevalence
of GC resistance. For example, in an independent study at
DHEC’s Richland County STD Clinic in 2006-2007, there
were 44 GC isolates from the 350 patients tested, all of
which were susceptible to ciprofloxacin. From principal
investigator communications, a similar susceptibility result
was reported from the Jackson, Mississippi site. However,
the Miami, Florida site reported different results in this
independent study. The Florida site had increased GC
resistance.
Unfortunately, many providers are not requesting
gonococcal STI susceptibilities because of the widespread
use of combination chlamydia and gonorrhea nucleic acid
amplification diagnostic tests. GC resistance testing
requires culturing the organism and this may not be readily
available. In addition, the demographic characteristics and
risk factors in the GISP population are very different from
those normally encountered in the southeast or publicly
funded STI clinics. This makes it difficult to generalize the
results from the GISP study.
In certain settings in South Carolina, ciprofloxacin may
stil l be a useful drug to treat gonococcal STI in
heterosexuals. However, targeted intramuscular
ceftriaxone should be used for men who have sex with
men and in individuals with a travel history west of the
Mississippi or to any large urban setting. Note that GC
treatment failure is defined as growth on culture seven
days after treatment because dead organisms will give a
reactive nucleic acid amplification test. This assumes no
reinfection and completion of treatment course as
prescribed. Return of symptoms is unreliable because of
an untreated partner, other causes of STIs (eg
trichomonas, chlamydia, Mycoplasma genitalium), and
initial empiric treatment. Patients with a history consistent
with treatment failure should have a GC culture sent for
susceptibility and have themselves and their partner
treated with intramuscular ceftriaxone. DHEC is presently
reviewing ways to monitor changing Neisseria gonorrhea
resistance prevalence in our state.
ReachSC and South Carolina Health
Alert Network
Shana Dorsey, BS, BA
DHEC, Division of Acute Disease Epidemiology
Reach South Carolina (ReachSC) is an interactive Web-
based notification system used for urgent public health
threats and events that require a statewide emergency
response.  It is managed jointly by the South Carolina
Department of Health and Environmental Control (DHEC)
and the S.C. Emergency Management Division (EMD).
The Health Alert Network (HAN) is a component of
ReachSC that will be used by DHEC for routine
communication and to distribute health alerts/advisories
from the U.S. Centers for Disease Control and Prevention
(CDC) and DHEC.  These health notifications can be sent
to public health partners by fax, phone, and email.  Health
notifications are sent to organization-defined points of
contact who then forward the message to appropriate
recipients according to their organization’s internal
communication plan.
There are many benefits of the ReachSC Health Alert
Network:
o It strengthens local public health
departments by connecting them to other
health care providers.
o It offers high-speed, around the clock
connection between network members.
o It provides an early warning system.
o It allows local, state and federal health
authorities to communicate and coordinate
quickly and securely with each other and with
Digitized by South Carolina State Library
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emergency management and law
enforcement.
o It notifies the public of public health threats
and provides important information in an
emergency.
Is your contact information in the ReachSC system
current?  Outdated contact information within the
ReachSC system may delay rapid alerts and notification.
Please make sure that your contact information remains
current.  If you are already registered in the ReachSC
system, you may update your contact information by
logging in to ReachSC (www.reachsc.com) using the user
ID and password created during the registration process.
If you would like to sign up and begin receiving health
notifications from HAN, contact the HAN coordinator at
DHEC by calling (803) 898-0431 or by e-mailing the
coordinator at dorseysl@dhec.sc.gov.  If the HAN
coordinator approves your request to receive health
notifications, you will receive an e-mailed invitation to
register for ReachSC.
Help DHEC Identify the Circulating
Strains of Influenza Virus in
South Carolina
Lena Bretous, MD, MPH
SC Influenza Surveillance Coordinator/Medical
Epidemiologist
DHEC, Division of Acute Disease Epidemiology
Participate in DHEC’s FREE influenza viral isolate
network and help DHEC alert health care providers and
the U.S. Centers for Disease Control and Prevention
(CDC) to the emergence of novel strains of influenza A or
B.  All DHEC-processed influenza isolates are reported
to the CDC. Upon CDC request, virus isolates are sent
for further characterization.
Enrollment is simple. Just contact Nena Turner at (803)
896-0819 to provide demographics, including license
number.
The DHEC Bureau of Laboratories suggest you confirm
your first rapid test results via a sampling (three to four
patients) of cultures at the beginning, middle, and end of
the influenza season.  After sending several patient
specimens for culture, please wait three to four weeks
before submitting additional cultures.
FREE:  Collection kits, ice packs, lab forms, instructions,
and postage-paid shipping materials are provided.  Kits
contain five specimen collection tubes. It is not necessary
to submit all five at once. Following shipment to the DHEC
Bureau of Laboratories, the shipping box will be returned
to you for additional use.
Please think of verifying respiratory illness clusters by
submitting FREE viral isolates to DHEC Laboratories.
Help DHEC Measure Influenza Burden in
South Carolina
Lena Bretous, MD, MPH
SC Influenza Surveillance Coordinator/Medical
Epidemiologist
DHEC, Division of Acute Disease Epidemiology
The U.S. Centers for Disease Control and Prevention (CDC)
Influenza-Like Illness (ILI) network bypasses laboratory
testing and focuses on respiratory signs and symptoms.
ILI is defined as: fever (≥ 100 Fahrenheit), cough, and/or a
sore throat in ABSENCE of other known cause.   This is the
fifth year that South Carolina is participating in the ILI network.
We encourage enrolled providers to take the brief time
needed each week to submit data via fax or internet to the
CDC.  Even during summer months, providers should
continue to submit data.  Zeros should be submitted if
applicable.
To enroll or reactivate your account, please contact Dr. Lena
Bretous at (803) 898-0862.  Once enrolled, the CDC will
mail a provider number and ID password.
Enrolled providers can register for free personalized S.C.
Weekly Flu Status emails.
? There were 34 providers who participated in the ILI
Surveillance Program with the CDC and DHEC this
past season.  Two more providers have already been
enrolled for the 2007-2008 season, which brings the
total actively enrolled to 36 providers.
? Twenty-four counties had a provider who submitted
data at least once during the season; 22 counties had
no active providers. Thus, out of the 46 counties in SC,
52 percent had providers who submitted data at least
once.
? Widespread activity status was attained from MMWR
week 52 through MMWR week 06. Thus, there were
seven straight weeks of “widespread” ILI activity in
the state this
season.
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Rabies and World Rabies Day –
September 8, 2007
Kira A. Christian, DVM, MPH
DHEC, Division of Acute Disease Epidemiology
Rabies is a preventable viral disease of mammals most
often transmitted through the bite of a rabid animal. The
vast majority of rabies cases reported to the U.S. Centers
for Disease Control and Prevention (CDC) each year occur
in wild animals like raccoons, skunks, bats, and foxes.
Domestic animals account for less than 10 percent of the
reported rabies cases, with cats, cattle, and dogs most
often reported rabid.
The rabies virus infects the central nervous system,
causing encephalopathy and, ultimately, death. Early
symptoms of rabies in humans are nonspecific, consisting
of fever, headache, and general malaise. As the disease
progresses, neurological symptoms appear and may
include insomnia, anxiety, confusion, slight or partial
paralysis, excitation, hallucinations, agitation,
hypersalivation, difficulty swallowing, and hydrophobia
(fear of water). Death usually occurs within days of the
onset of symptoms.
There is no treatment for rabies after symptoms of the
disease appear. However, two decades ago scientists
developed an extremely effective new rabies vaccine
regimen that provides immunity to rabies when
administered after an exposure (postexposure prophylaxis)
or for protection before an exposure occurs (preexposure
prophylaxis). Although rabies among humans is rare in
the United States, every year an estimated 18,000 people
receive rabies preexposure prophylaxis and an additional
40,000 receive postexposure prophylaxis. Each year in
South Carolina, about 400 people receive postexposure
prophylaxis.
In this century, the number of human deaths in the United
States attributed to rabies has declined from 100 or more
each year to an average of one or two each year. Two
programs have been responsible for this decline. First,
animal control and vaccination programs begun in the
1940s have practically eliminated domestic dogs as
reservoirs of rabies in the United States. Second, effective
human rabies vaccines and immunolglobins have been
developed.
World Rabies Day was organized to raise awareness of
human and animal rabies, educate the public on
prevention measures, and prioritize elimination strategies.
The CDC held the first annual CDC World Rabies Day
Symposium and Expo on September 7, 2007, in
conjunction with the first annual World Rabies Day (officially
on September 8, 2007). The purpose of the meeting was
to discuss historical progress and future needs in rabies
prevention and control. International scientists, public
health professionals, veterinarians, professional
audiences, and the general public attended the
symposium and developed relationships to ensure
ongoing rabies awareness and prevention efforts.
Three staff from the  South Carolina Department of Health
and Environmental Control attended the CDC World
Rabies Day Symposium and Expo: Dr. Robert Ball, Dr. Eric
Brenner, and Dr. Kira Christian.
Learn more about World Rabies Day at: http://
www.worldrabiesday.org/index_en.php
Learn more about the CDC World Rabies Day
Symposium and Expo at:
http://www.cdc.gov/worldrabiesday/
For further information, please contact:
Dr. Kira Christian
803-898-2110
christka@dhec.sc.gov
Reference: www.cdc.gov
Public Health Clinical Liaisons: Assisting
South Carolina Medical Practices with
Pandemic Influenza Preparedness
Rosica Hardee, RN, MPH
DHEC, Division of Acute Disease Epidemiology
The South Carolina Department of Health and
Environmental Control (SC DHEC) has established a novel
way of addressing front-line healthcare provider readiness
for pandemic influenza.  Regional Public Health Clinical
Liaisons (PHCLs) are available to help medical practices
and Emergency Departments prepare for their roles during
Pandemic Influenza. Funded by a CDC Pandemic Influenza
Supplemental Grant, most of these are retired Public Health
Nurses with many years of public health nursing
Digitized by South Carolina State Library
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experience who have stepped right into these roles with
great enthusiasm and gusto. Their main modes of training
resemble pharmaceutical “detailing.” Training involves
visits to medical practices and face-to-face presentations
to small groups of nurses and other staff. The PHCLs
offer a highly focused set of activities that the practices
can adopt to increase their ability to cope with a pandemic.
Medical practice groups can tailor the disease control
activities to their specific organization, patient
characteristics, and personnel skills.  The trainers offer a
“practice readiness assessment” up front, followed by a
pandemic influenza overview.
The practice skills are offered in four modules, each of
which can be presented to a medical practice to educate
staff on key preparedness components.  A practice can
choose targeted training using one module based upon
their perceived need or limited training time. Or, a practice
can establish a training schedule for each of the four
modules to provide a broader perspective on how the
practice can prepare for the potential impact of pandemic
influenza.
The four modules are:
   Module 1: Preparation of practice to become a
sentinel Influenza-like-illness (ILI)
reporting source and/or sentinel
influenza culture surveillance participant,
   Module 2: Infection control in the practice in the face
of pandemic influenza,
   Module 3: Community disease control activities
and patient education,
   Module 4: Continuity of operations: Planning for
the practice.
Along with a pandemic influenza notebook containing each
of the four modules, supporting information, checklists,
and resources, providers are also offered colorful posters
to help patients and staff improve cough etiquette, hand
hygiene, and other infection control activities.
Medical practice enrollment as ILI sentinel providers and
influenza culture surveillance participants has increased
since the PHCLs began working with practices. Follow-up
visits have revealed increasing implementation of infection
control policies and practices. Evaluations are being
administered to practices to analyze the effectiveness of
PHCL activities.
For further information or PHCL contact information, call
Dr. Lena Bretous at (803) 898-0862 or Roscia Hardee,
RN, at (803) 898-1490.
Ask Epi
Infectious Disease Information
Eric Brenner, MD
Medical Epidemiologist
DHEC, Division of Acute Disease Epidemiology
The DHEC Bureau of Disease Control regularly receives
questions from physicians, hospitals, and local public
health departments regarding disease control,
epidemiology, and public health issues.  We occasionally
publish questions and replies that may be of general
interest. Questions may be submitted to:
askEpi@sc.dhec.gov
Question:  In our community, DHEC disease control
consultants have recently helped resolve several thorny
communicable disease questions for which answers were
not readily available in the usual internal medicine,
pediatric, or other standard texts. Which references do your
in-house DHEC consultants typically use?
Answer: This is an excellent question. Certainly we, like
everyone else these days, struggle to have just the right
mix of paper and electronic resources at our fingertips so
we can keep up with the barrage of questions and issues
we face every day. One good source of general information
about communicable disease reports in South Carolina
is DHEC’s Annual Disease Summary, which is posted on
the Web (1). More generally, the CDC’s Web home page
(www.cdc.gov) provides an excellent entry point for
information.  An especially friendly feature of the page is
the mini-on-screen A – Z typewriter, which lets users quickly
find a disease topic of interest.  For example, clicking on
“W” will take you to Water-related diseases, West Nile
Virus, Whooping Cough and more. (Access to the CDC
alphabet soup listings is even more direct through
www.cdc.gov/az).  A similar Web information portal is run
by the National Institutes of Health. (http://medlineplus.gov
and www.nlm.nih.gov/medlineplus/healthtopics.html) Both
the CDC and NIH sites are great sources for patients
seeking reliable information.
For a general reference about both clinical and community
aspects of infectious diseases, it’s hard to beat the
American Academy of Pediatrics Red Book (2). Most of
Digitized by South Carolina State Library
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DHEC’s central office and regional medical consultants
are not pediatricians, but our consulting nurses,
physicians, and epidemiologists never venture far from
their Red Book, especially when taking calls. In addition to
standard textbook-style summaries about clinical
manifestations of disease, diagnosis, and treatment, the
Red Book includes community-oriented sections on
disease reservoir, mode of transmission, period of
communicability, isolation precautions, and control
measures. It’s a real treasure. Slightly more esoteric, but
much more portable, is the Control of Communicable
Disease Manual (3). Like the Red Book it is organized
alphabetically by disease and, if anything, places even
greater emphasis on practical community health issues.
Somewhat more specialized are the CDC’s
Recommendations and Reports (RR) series.  These are
related to the CDC’s more famous Morbidity and Mortality
Weekly Report (MMWR), but the RR series should not be
confused with the “plain-vanilla” weekly MMWRs (however
interesting the short articles in the weekly edition may be).
Rather, each issue of the RR series provides an in-depth
mini-reference or authoritative recommendations about a
particular topic.  A recent example was the March 23, 2007,
RR issue introducing the new Human Papilloma Virus
(HPV) vaccine (4). Recent RRs have also addressed
influenza vaccine issues (updated yearly in the RR series),
numerous other recommendations regarding
immunization, HIV testing, treatment of STDs, diagnosis
and management of tick-borne diseases, and much more.
RR issues are published about a dozen times per year,
and issues going back to 1990 can be downloaded in
PDF format from www.cdc.gov/mmwr.
Aside from these paper and electronic resources, DHEC
consultants constantly seek advice and information from
one another, not only in Columbia, but throughout the state.
Although all of our consultants try to be generalists, in the
natural course of things some of us have become more
knowledgeable about particular subjects. So, for complex
questions, or when the health of a group is at stake, we
adhere to the adage several heads are better than one.
We collaborate with our colleagues either right down the
hall or by phone.  Finally, we communicate frequently with
our counterparts in other state public health departments
(e.g. with those in North Carolina or Georgia for cross-
border issues). We communicate almost daily with
colleagues at the U.S. Centers for Disease Control (CDC),
frequently seeking advice or opinions from its many highly
specialized consultants.
In summary, we commonly use a number of useful
reference manuals and make extensive use of Web
resources. Beyond that, we benefit from the counsel of
experienced colleagues both in-house and around the
country. All these resources are available directly or
indirectly to physicians from around the state. We’re always
pleased to consult with physicians and other health care
professionals.(5).
References (*)
1. 2005 South Carolina Annual Report on Reportable
Conditions.  Available from DHEC’s Web site at:
www.dhec.sc.gov/health/disease/docs/
Annual_Report_on_Reportable_Conditions.pdf.
2. Red Book.  2006 Report of the Committee on
Infectious Diseases, 27th edition. (2006) American
Academy of Pediatrics.
3. Control of Communicable Disease Manual.
American Public Health Association 18th Edition
(2004) David Heymann Editor.
4. Quadrivalent Human Papillomavirus Vaccine
Recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR March 23,
2007 / Vol. 56 / No. RR—2.
5. At the state level, consultations are available
through the Division of Acute Disease Epidemiology
at (803) 898 – 0861. DHEC’s regional disease
consultants may be reached through your local
public health department.
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Condition  Confirmed  Probable Total 
Animal Bite—PEP Recommended 273 * 273 
Aseptic m eningitis 71 0 72 
Brucellosis 2 0 2 
Cam pylobacteriosis 188 1 189 
Ciguatera fish poisoning 1 0 1 
Cryptosporidiosis 54 * 54 
Cyclosporiasis 1 * 1 
Dengue Fever 1 1 2 
Ehrlichiosis- human granulocytic 1 0 1 
Ehrlichiosis- human monocytic 1 2 3 
Ehrlichiosis- human- other&unspec 1 1 2 
Encephalitis- W est Nile 1 0 1 
Enterohem. E.coli O157:H7 4 0 4 
Enterohem.E.coli shigatox+- ?serogrp 0 0 0 
Enterohem.E.coli- shigatox+- non-O157 1 0 1 
Giardiasis 75 0 75 
Group A Streptococcus- invasive 78 0 78 
Group B Streptococcus- invasive 25 0 25 
Haem ophilus influenzae- invasive 37 0 37 
Hem olytic uremic synd- postdiarrheal 1 0 1 
Hepatitis A- acute 12 0 12 
Hepatitis B- acute 13 0 13 
Hepatitis B virus infection—Chronic 166 266 432 
Hepatitis B virus infection—Perinatal 0 0 0 
Hepatitis C- acute 0 0 0 
Hepatitis C Virus Infection- past or present 2884 425 3309 
Hepatitis Delta co- or super-infection- acute 0 0 0 
Hepatitis E- acute 1 0 1 
Influenza- human isolates 65 0 65 
Legionellosis 12 1 13 
Listeriosis 8 0 8 
Lym e disease 22 0 22 
Malaria 5 0 5 
Mumps 1 0 1 
Neisseria m eningitidis- invasive (Mening. disease) 13 0 13 
Pertussis 44 10 54 
Rocky Mountain spotted fever 14 41 55 
S. aureus, vancom ycin interm ediate susc (VISA) 2 0 2 
Salmonellosis 770 4 774 
Shiga toxin-producing Escherichia coli (STEC) 8 0 8 
Shigellosis 108 0 108 
Strep pneumoniae- invasive 237 0 237 
Streptococcal disease- invasive- other 6 0 6 
Tetanus 0 0 0 
Toxic-shock syndrom e- staphylococcal 0 0 0 
Varicella (Chickenpox) 460 320 780 
Vibrio parahaem olyticus 1 0 1 
Vibrio spp.- non-toxigenic- other or unspecified 5 0 5 
Vibrio vulnificus infection 0 0 0 
West Nile Fever 1 1 2 
Yersiniosis 5 1 6 
 
*Probable status is not allowed for this condition.
Digitized by South Carolina State Library
Epi-Notes
Division of Acute Disease Epidemiology
SC DHEC
2600 Bull Street
Columbia, SC  29201
Editorial Staff
Editors: Libby C. Greene, MSN, APRN, BC
Karen Addy, BA
Data Manager:    Claire Youngblood, MA
Design and Layout:    Gloria A. McCurry
THE EPI NOTES NEWSLETTER IS NOW AVAILABLE ON LINE AT
www.scdhec.gov/health/disease/index.htm
Bureau of Disease Control
J. Gibson, MD, MPH, Director
803-898-0861
Bureau of Disease Control Divisions
Division of Acute Disease Epidemiology
803-898-0861
Division of Immunization
1-800-277-4687
Division of STD/HIV
803-898-0749
Division of Surveillance and Technical Support
803-898-0749
Division of Tuberculosis Control
803-898-0558
For immediately reportable conditions, call your local
county  health department or,  for after-hours, call
1-888-847-0902. Routine reports may be phoned in to
your local health department or mailed on a completed
DHEC DISEASE REPORTING CARD (DHEC 1129) .  Local
FOR DISEASE REPORTING
county health department numbers are listed on the
Official List of Reportable Conditions.  For a copy of the
current Official List of Reportable Conditions, call
803-898-0861 or visit
www.scdhec.gov/health/disease/index.htm
Epi-Notes is published by the South Carolina
Department of Health and Environmental Control
Division of Acute Disease Epidemiology
Digitized by South Carolina State Library
-~_ .......
_. .-
